The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma

Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy

(2016) Jia Ruan et al.   Current Hematologic Malignancy Reports

Unknown

(2016)   AMERICAN JOURNAL OF HEMATOLOGY

Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management

(2015) Julie M. Vose   AMERICAN JOURNAL OF HEMATOLOGY

A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

(2015) Timothy S. Fenske et al.   CANCER

Treatment options for mantle cell lymphoma

(2015) Piotr Smolewski et al.   EXPERT OPINION ON PHARMACOTHERAPY

Deubiquitinases (DUBs) and DUB inhibitors: a patent review

(2015) Pershang Farshi et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series

(2015) Ariz Akhter et al.   JOURNAL OF CLINICAL PATHOLOGY

Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor

(2015) S. Rosebeck et al.   MOLECULAR CANCER THERAPEUTICS

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

(2015) Tadeusz Robak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: insights from mdm2 and mdm4 mutant zebrafish

(2015) J S Chua et al.   ONCOGENE

Deubiquitinase inhibition as a cancer therapeutic strategy

(2015) Padraig D'Arcy et al.   PHARMACOLOGY & THERAPEUTICS

Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib

(2015) Ling Peng et al.   SUPPORTIVE CARE IN CANCER

Putative E3 Ubiquitin Ligase of Human Rotavirus Inhibits NF-κB Activation by Using Molecular Mimicry To Target β-TrCP

(2015) Marco Morelli et al.   mBio

Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma

(2015) Violetta V. Leshchenko et al.   Oncotarget

Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance

(2015) Areumnuri Kim et al.   Oncotarget

Arsenic trioxide rewires mantle cell lymphoma response to bortezomib

(2015) Ling-Ling Zhao et al.   Cancer Medicine

RNF115/BCA2 E3 Ubiquitin Ligase Promotes Breast Cancer Cell Proliferation through Targeting p21Waf1/Cip1 for Ubiquitin-Mediated Degradation

(2015) Zehua Wang et al.   NEOPLASIA

The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells

(2014) J. Zhang et al.   BLOOD

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study

(2014) Michael Wang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Emerging Potential of Therapeutic Targeting of Ubiquitin-Specific Proteases in the Treatment of Cancer

(2014) A. Pal et al.   CANCER RESEARCH

Histone H2B monoubiquitination: roles to play in human malignancy

(2014) Alexander J Cole et al.   ENDOCRINE-RELATED CANCER

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)

(2014) Vicki A. Morrison et al.   LEUKEMIA & LYMPHOMA

Cullin 4A and 4B ubiquitin ligases interact with γ-tubulin and induce its polyubiquitination

(2014) Anand Thirunavukarasou et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Regulation of proteolysis by human deubiquitinating enzymes

(2013) Ziad M. Eletr et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Targeting the ubiquitin–proteasome system for cancer therapy

(2013) Min Shen et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma

(2013) Rami Rahal et al.   NATURE MEDICINE

Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells

(2013) Sabrina Manni et al.   PLoS One

Landscape of somatic mutations and clonal evolution in mantle cell lymphoma

(2013) S. Bea et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities

(2012) H. J. Jung et al.   BLOOD

Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features

(2012) A. Navarro et al.   CANCER RESEARCH

Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma

(2012) S. Xargay-Torrent et al.   CLINICAL CANCER RESEARCH

Molecular pathogenesis of mantle cell lymphoma

(2012) Pedro Jares et al.   JOURNAL OF CLINICAL INVESTIGATION

The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells

(2012) Areumnuri Kim et al.   LEUKEMIA RESEARCH

Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA

(2012) R. J. Jones et al.   MOLECULAR CANCER THERAPEUTICS

Blocking Autophagy Prevents Bortezomib-Induced NF-κB Activation by Reducing I-κBα Degradation in Lymphoma Cells

(2012) Li Jia et al.   PLoS One

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

(2011) J. W. Friedberg et al.   BLOOD

Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma

(2011) R. Kridel et al.   BLOOD

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

(2011) D. Chen et al.   CURRENT CANCER DRUG TARGETS

Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma

(2011) Hyun Joo Jung et al.   EXPERIMENTAL HEMATOLOGY

Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group

(2011) Laurie H. Sehn et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel Proteasome Inhibitors to Overcome Bortezomib Resistance

(2011) Amy M. Ruschak et al.   JNCI-Journal of the National Cancer Institute

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)

(2011) C. Tom Kouroukis et al.   LEUKEMIA & LYMPHOMA

Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress, and induces caspase-dependent cell death in antiestrogen–sensitive and resistant ER+ breast cancer cells

(2010) Sudharsan Periyasamy-Thandavan et al.   Autophagy

The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78

(2010) G. Roue et al.   BLOOD

Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation

(2010) P. Perez-Galan et al.   BLOOD

Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

(2010) Jorge E. Romaguera et al.   BRITISH JOURNAL OF HAEMATOLOGY

Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia

(2010) Agathoclis Agathocleous et al.   BRITISH JOURNAL OF HAEMATOLOGY

Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes

(2010) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma

(2010) Lapo Alinari et al.   mAbs

PRDM1 Is Required for Mantle Cell Lymphoma Response to Bortezomib

(2010) S. Desai et al.   MOLECULAR CANCER RESEARCH

Degrasyn Potentiates the Antitumor Effects of Bortezomib in Mantle Cell Lymphoma Cells In vitro and In vivo: Therapeutic Implications

(2010) L. V. Pham et al.   MOLECULAR CANCER THERAPEUTICS

Gene expression profiling in lymphoma diagnosis and management

(2009) Javeed Iqbal et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

(2009) N. Di Bella et al.   BLOOD

Fludarabine, Bortezomib, Myocet®and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma

(2009) Enrico Orciuolo et al.   BRITISH JOURNAL OF HAEMATOLOGY

The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins

(2009) Sjoerd J. L. van Wijk et al.   FASEB JOURNAL

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study

(2009) Oliver Weigert et al.   LEUKEMIA & LYMPHOMA

Ubiquitinated Proteins Activate the Proteasome by Binding to Usp14/Ubp6, which Causes 20S Gate Opening

(2009) Andreas Peth et al.   MOLECULAR CELL

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

(2008) A. Goy et al.   ANNALS OF ONCOLOGY

Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes

(2008) V. K. Prasad et al.   BLOOD

Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways

(2008) Edgar Gil Rizzatti et al.   LEUKEMIA & LYMPHOMA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE